Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | CCR8 | P51685 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | SDHB | P21912 | 1/20 | 0.37 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361055 | 0.81 | KDM4E (0.52) | CCR1CCR8PTGS2KDM4EALDH1A1 | |
| SCHEMBL30637352 | 0.80 | NPSR1 (0.42) | NPSR1KDM4EALDH1A1HPGD | |
| SCHEMBL4138614 | 0.80 | NPSR1 (0.42) | NPSR1KDM4EALDH1A1HPGD | |
| SCHEMBL410999 | 0.78 | CDK2 (0.47) | NPSR1KDM4EALDH1A1EGFRCYP3A4 | |
| SCHEMBL30122726 | 0.78 | SDHB (0.47) | SDHBBPTFNPSR1KDM4EALDH1A1 | |
| SCHEMBL3359085 | 0.78 | TGFBR1 (0.42) | CCR1CCR8CYP2A6PTGS2TGFBR1 | |
| SCHEMBL413588 | 0.77 | GAA (0.40) | TGFBR1MAPK14KDRRIPK2NPSR1 | |
| SCHEMBL409797 | 0.76 | EGFR (0.41) | TGFBR1MAPK14KDRRIPK2NPSR1 | |
| SCHEMBL29290793 | 0.76 | HSP90AA1 (0.48) | EGFRCYP3A4BRAFJAK3MAPK10 | |
| SCHEMBL4447801 | 0.76 | BPTF (0.54) | PTGS2SDHBBPTFNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| EP-2007751-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007113260-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113260-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | DRD3, DRD2, HTR3A | CCR1 4136/4885CCR8 4394/4885CYP2A6 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.